ClinicalTrials.gg
Not yet recruitingNCT07830953Updated Oct 5, 2026

SharkScrew ACL RCT

An interventional study of ACL Reconstruction with a Biocomposite Screw and ACL Reconstruction using a PEEK Screw in ACL - Anterior Cruciate Ligament Rupture, sponsored by Austrian Workers Compensation Board Styria. Not yet recruiting at 1 site in Austria. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Austrian Workers Compensation Board Styria · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This prospective, randomized controlled trial will compare three tibial interference screw types used for graft fixation during primary anterior cruciate ligament (ACL) reconstruction: a polyetheretherketone (PEEK) screw, a biocomposite screw, and an allograft bone screw. Although interference screws are widely used for tibial fixation, the optimal screw material remains uncertain, particularly regarding its effect on tibial tunnel widening and graft incorporation.

Adult patients undergoing primary ACL reconstruction with a quadriceps tendon autograft using a standardized surgical technique will be randomly assigned to one of the three tibial fixation methods. The primary outcome is tibial tunnel widening measured by computed tomography (CT) 12 months after surgery. Secondary outcomes include graft integration assessed by magnetic resonance imaging (MRI) and patient-reported clinical outcomes, including the Lysholm, Tegner, KOOS, and ACL-Return to Sport after Injury (ACL-RSI) scores, collected during routine follow-up. The study aims to determine whether allograft bone screws reduce tunnel widening and improve graft integration compared with PEEK and biocomposite screws while maintaining comparable clinical outcomes.

Read the detailed description

For the **ClinicalTrials.gov Detailed Description**, you generally want a more comprehensive description of the rationale, design, interventions, and objectives without reproducing the entire protocol. Here's a version suitable for direct use:

---

**Detailed Description**

Anterior cruciate ligament (ACL) reconstruction is the standard surgical treatment for symptomatic ACL rupture, with interference screw fixation being the most commonly used method for tibial graft fixation. While current fixation techniques provide reliable mechanical stability, the optimal screw material remains uncertain. Commonly used polyetheretherketone (PEEK) screws are biologically inert and provide durable fixation but do not integrate with surrounding bone. Biocomposite screws are designed to gradually resorb while promoting bone ingrowth; however, their degradation characteristics have been associated with variable tunnel widening. More recently, allograft bone interference screws have been introduced as a biological alternative that may allow complete osseous incorporation while maintaining adequate initial fixation. Clinical evidence directly comparing these three fixation methods remains limited, particularly regarding their effects on tibial tunnel widening, graft incorporation, and patient outcomes.

This prospective, single-center, randomized controlled trial will compare tibial fixation using a PEEK screw, a biocomposite screw, or an allograft bone screw in patients undergoing primary ACL reconstruction. All participants will undergo reconstruction using a standardized SAMBBA technique with an ipsilateral quadriceps tendon autograft. Femoral fixation will be identical in all patients, with only the tibial interference screw differing between treatment groups. Participants will be randomized in a 1:1:1 allocation ratio using sealed envelopes. Patients, physiotherapists, and outcome assessors will remain blinded to treatment allocation throughout follow-up.

The primary endpoint is tibial tunnel widening measured on computed tomography (CT) 12 months after surgery. Secondary endpoints include graft incorporation assessed by magnetic resonance imaging (MRI) according to the method described by Putnis et al., as well as validated patient-reported outcome measures including the Lysholm Score, Tegner Activity Scale, Knee Injury and Osteoarthritis Outcome Score (KOOS), and ACL-Return to Sport after Injury (ACL-RSI). Clinical and radiographic follow-up will be performed according to the study schedule over 12 months after surgery.

The study is designed to determine whether allograft bone interference screws reduce tibial tunnel widening and improve biological graft integration compared with conventional PEEK and biocomposite screws while maintaining equivalent clinical outcomes. The findings are expected to provide high-quality evidence to guide the selection of tibial fixation devices in primary ACL reconstruction.

02

Conditions studied

  • ACL - Anterior Cruciate Ligament Rupture

Keywords

  • ACL Rupture
  • ACL Reconstruction
03

In context

Anterior Cruciate Ligament Injuries

625 studies on the registry are indexed under Anterior Cruciate Ligament Injuries; 192 are open to participants now.

This study's planned enrollment of 33 is below the median of 56 across 458 interventional studies indexed under Anterior Cruciate Ligament Injuries.

Browse Anterior Cruciate Ligament Injuries studies →

Lead sponsor

Austrian Workers Compensation Board Styria is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and non-pregnant female patients aged 18-70 years
  • MRI-confirmed rupture of the anterior cruciate ligament (ACL)
  • Clinically positive anterior drawer test and Lachman test
  • Subjective instability
  • Clinically and MRI-confirmed intact posterior cruciate ligament (PCL), medial collateral ligament (MCL), and posterolateral corner
  • Written obtained
  • Patient is able and willing to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Previous surgery on the affected knee joint (ACL reconstruction, fracture fixation, osteotomy, or partial joint replacement)
  • (BMI) > 40
  • Coronal instability due to injury of the medial collateral ligament or posterolateral corner
  • Meniscal injury requiring postoperative restriction of weight-bearing (e.g., root tears, radial tears)
  • The patient is unable to speak German
  • The patient is pregnant
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
33 participants (estimated)

Study arms

  • Active comparator
    Biocomposite Interference Screw

    Biocomposite Interference Screw Fixation of the Tibial End of the Graft

    Procedure: ACL Reconstruction with a Biocomposite Screw

  • Active comparator
    PEEK Interference Screw

    Polyether Ether Ketone Interference Screw Fixation of the Tibial End of the Graft

    Procedure: ACL Reconstruction using a PEEK Screw

  • Experimental
    Shark Screw

    Allograft Bone Interference Screw Fixation of the Tibial End of the Graft

    Procedure: ACL Reconstruction using an Allograft Screw

Interventions

  • ProcedureACL Reconstruction with a Biocomposite Screw

    ACL Reconstruction using a standardized technique. Tibial Fixation using a Biocomposite Screw.

  • ProcedureACL Reconstruction using a PEEK Screw

    ACL Reconstruction using a standardized technique. Tibial Fixation using a PEEK Screw.

  • ProcedureACL Reconstruction using an Allograft Screw

    ACL Reconstruction using a standardized technique. Tibial Fixation using a SharkScrew Allograft Interference Screw.

06

What researchers measure

Primary outcomes

  1. Tibial Tunnel Widening

    CT Measurement of the tibial Tunnel Widening in mm. The difference will be calculated between drilled diameter and measured diameter.

    Time frame: 1 Year Postop

Secondary outcomes

  1. MRI Graft Integration

    MRI Graft Integration using SNL Coefficient. Baseline PCL graft signal on fat suppressed T2 will be compared to the ACL in 3 zones, tibial, intraarticular and femoral. The technique is described in detail in Putnis SE, Klasan A, Oshima T, Grasso S, Neri T, Coolican MRJ, Fritsch BA, Parker DA. Magnetic Resonance Imaging Assessment of Hamstring Graft Healing and Integration 1 and Minimum 2 Years after ACL Reconstruction. Am J Sports Med. 2022 Jul;50(8):2102-2110. doi: 10.1177/03635465221096672. Epub 2022 May 25. PMID: 35612835.

    Time frame: 6 Months and 1 Year

  2. Lysholm

    Lysholm Questionnaire scores will be assessed. Possible value 0-100. Higher is better.

    Time frame: 1 Year postop

  3. Tegner

    Tegner Questionnaire will be assessed. Range 0-10, higher is better.

    Time frame: Preop, 1 year postop

  4. ACL-RSI

    ACL-RSI Questionnaire will be assessed. 0-100, higher is better.

    Time frame: 12 month postop

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2028, 25 months later.

Of 278 non-industry interventional studies with no phase under Anterior Cruciate Ligament Injuries, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 70. This study's planned 25 months is below that.

Counting every sponsor, half of 287 studies reached it within 30 months; a quarter within 14 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2026
First posted
Sep 21, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
3 description edited
What changed in the outcomes
  • DescriptionACL-RSI: how it is measured was reworded
  • DescriptionLysholm: how it is measured was reworded
  • DescriptionTegner: how it is measured was reworded
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Secondary outcomes 3 description edited
    What changed in the outcomes
    • DescriptionACL-RSI: how it is measured was reworded
    • DescriptionLysholm: how it is measured was reworded
    • DescriptionTegner: how it is measured was reworded

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07830953
Lead sponsor
Austrian Workers Compensation Board Styria
Responsible party
Sponsor
First posted
Sep 21, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Antonio Klasan, MD, PhD, EMBA, FRCS
Contact
klasan.antonio@me.com
+43 676 5085920

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion